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Abstract 20 
Background 21 
The development of a standardised reporting set is important to ensure that research is directed 22 
towards the most important outcomes and that data are comparable. To ensure validity, the set must 23 
be agreed by a consensus of stakeholders including patients, healthcare professionals and lay 24 
representatives. There is currently no agreed core outcome set for patients undergoing major lower 25 
limb amputation for peripheral arterial disease (PAD) for either short or medium term research 26 
outcomes.  By developing these sets we aim to rationalise future trial outcomes, facilitate meta-27 
analysis and improve the quality and applicability of amputation research.  28 
Methods/Design 29 
We will undertake a comprehensive systematic review of studies of patients undergoing major lower 30 
limb amputation for PAD. Data regarding all primary and secondary outcomes reported in relevant 31 
studies will be extracted and summarised as outcome domains.  We will then undertake focus groups 32 
with key stakeholders (patients, carers, health and social care workers) to collect qualitative data to 33 
identify the main short and medium term research outcomes for patients undergoing major lower 34 
limb amputation. Results of the systematic review and focus groups will be combined to create a 35 
comprehensive list of potential key outcomes.  Stakeholders (patients, researchers and health and 36 
social care workers) will then be polled to determine which of the outcomes are considered to be 37 
important in a general context using a 3-phase Delphi process.  After preliminary analysis, results will 38 
be presented at a face-to-face meeting of key stakeholders for discussion and voting on the final set 39 
of core outcomes. This project is being run in parallel with a feasibility trial assessing perineural 40 
catheters in patients undergoing lower limb amputation (the PLACEMENT trial).  Full ethical approval 41 
has been granted for the study (Wales REC 3 reference number 16/WA/0353). 42 
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Discussion 43 
Core outcome sets will be developed for short and medium term outcomes of research involving 44 
patients undergoing major lower limb amputation for PAD.  This will help with the design of future 45 
trials and facilitate meta-analyses of trial data. 46 
Trial registration 47 
PROSPERO: CRD42017059329 (Registered 30 March 2017). 48 
COMET: 675 (Registered 5 April 2017). 49 
Keywords 50 
Amputation, Peripheral arterial disease, Vascular Surgical Procedures, Outcome Assessment (Health 51 
Care) 52 
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Background 54 
The rising prevalence of diabetes combined with high historical rates of smoking have resulted in 55 
global levels of peripheral arterial disease (PAD) exceeding 10% in 65-69 year olds [1].  Despite 56 
advances in techniques for revascularisation, a small but significant proportion (1-2%) of these 57 
patients will progress to non-reconstructable or non-salvageable PAD, and be faced with major 58 
lower limb amputation [2].  This has led to approximately 5000 major lower limb amputations being 59 
performed each year in the United Kingdom alone [3]. A recent UK-wide report highlighted the 60 
substandard outcomes experienced by these patients; including poor pain control, delays getting 61 
patients to the operating room and high rates of in-hospital mortality [2].  Outcomes in the UK 62 
appear to be worse than in other developed countries [2].  There is therefore an urgent need for 63 
research into improving outcomes for patients undergoing lower limb amputation. 64 
Systematic review with meta-analysis is the optimal strategy for pooling results from multiple 65 
studies, but it is increasingly realised that many studies involving similar patient cohorts report 66 
similar but subtly different outcomes [4].  This heterogeneity makes meta-analysis difficult, and it is 67 
often impossible to generate pooled effect estimates [5].  This can result in studies being excluded 68 
from analysis simply because their outcomes are not directly comparable.  In response to this issue, 69 
a growing number of “Core Outcome Sets” have been developed [6].  Core outcome sets aim to find 70 
consensus on which key outcomes should be reported for all studies involving a particular group of 71 
patients, presenting a minimum standard.  If adopted, future research will then be more directly 72 
comparable.  In addition to this, they aim to reduce research waste by directing research towards 73 
the most important outcomes, and reduce the under-reporting of harms by listing the important 74 
harms which should be reported in clinical studies. 75 
Although there has been some work examining core outcomes for longer term functional issues in 76 
established amputees [7], there is no consensus about which short (within 30 days) and medium 77 
term (up to 2 years) outcomes are important to report for patients undergoing major lower limb 78 
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amputation. These definitions of short term and medium term were chosen because many 79 
established quality metrics in surgery are concerned with outcomes such as mortality or readmission 80 
within 30 days; and after consulting colleagues in rehabilitation, who told us that they would regard 81 
patients 2 years after their amputation as ‘established’ amputees.  There is currently a significant 82 
focus on the poor short and medium term outcomes of amputees in the UK [3], so it is vitally 83 
important that core outcomes sets for both short and medium term outcomes are developed soon. 84 
These should then be reported in any study involving patients undergoing major lower limb 85 
amputation.  The lack of core outcome sets for patients undergoing major lower limb amputation 86 
was evident to the authors when designing a randomised controlled feasibility trial examining the 87 
use of a perineural catheter to improve pain following major lower limb amputation (PLACEMENT 88 
trial) [8].  Development of these core outcome sets will therefore be undertaken in tandem with this 89 
study (Wales REC 3 reference number 16/WA/0353). 90 
The aim of the current work is to develop core outcome sets for short and medium term outcomes 91 
for research involving patients undergoing major lower limb amputation for complications of 92 
peripheral vascular disease.  The reason for restricting attention to this subgroup of amputees and 93 
excluding those patients undergoing amputation for other reasons, such as trauma or tumour, is 94 
that these two subsets of patients are quite distinct.  Patients undergoing amputation for 95 
complications of peripheral vascular disease are generally older, with significant co-morbidities.  96 
Patients undergoing amputation for trauma or tumour are generally younger, and often otherwise 97 
healthy.  The latter patient group often return to full independence quickly, whereas the former 98 
have a significant risk of not even surviving admission, and often have a prolonged, difficult 99 
rehabilitation phase.  It was therefore felt that core outcomes for the two groups might be quite 100 
different, so we focussed attention on the larger subset, which in most countries is the subset with 101 
peripheral vascular disease. 102 
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Drawing upon methods used in the development of previous core outcome sets and described in 103 
The COMET Handbook [9], the study will take a mixed-methods approach [10], utilising both 104 
quantitative and qualitative aspects.  It will be undertaken in four key stages as described in the 105 
Handbook:  (I) a systematic review to identify existing published outcomes; (II) focus groups to 106 
ensure that published outcomes adequately capture the issues which are most important to patients 107 
undergoing amputation as well as those who care for them; (III) a consensus (Delphi) survey; and (IV) 108 
generation of the final core outcome set using the results of the consensus survey and a nominal 109 
group technique.  The objective of this report is to describe a protocol for development of a core 110 
outcome set for studies of major lower limb amputation for peripheral vascular disease using this 111 
process. 112 
Methods 113 
Phase I: Systematic review 114 
The first stage of core outcome set development will involve a systematic review of published 115 
literature.  The objective of this phase is to create a long-list of outcome measures which have been 116 
reported in previous studies.  The review will be conducted according to the PRISMA statement as 117 
appropriate [11], and has been registered in the PROSPERO registry (ID: CRD42017059329).  118 
Criteria for considering studies 119 
All clinical studies reporting at least one short (within 30 days) or medium term (up to 2 years) 120 
outcome involving human subjects undergoing major lower limb amputation (i.e. amputation of the 121 
lower limb above the ankle) as a result of PAD will be included.  This includes non-interventional 122 
studies (e.g. case series, cohort and qualitative studies), non-randomised and randomised 123 
interventional trials.  Study reports describing the same patient sample will be included if they 124 
report different outcomes, but outcomes which are duplicated will only be counted once in any 125 
quantification of the frequency of outcome reporting.  Studies reporting only patients undergoing 126 
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amputation for non-ischaemic disease such as trauma, tumour, chronic non-ischaemic pain or 127 
congenital malformations will be excluded.  Systematic reviews will be included as providing a 128 
source of additional references which might otherwise be missed.  Non-systematic reviews, 129 
commentary, editorials and articles which discuss general principles rather than patient cases will be 130 
excluded.  Non-English language clinical studies will be included if there is a publicly available 131 
translation of either the abstract or full study, and data extraction will be limited to what is available 132 
in English.   133 
Outcomes 134 
All outcomes described as either primary or secondary outcomes from included studies will be 135 
reported. When more than a single study reports an outcome, the number and proportion of studies 136 
reporting that outcome will be recorded. 137 
Search strategy 138 
MEDLINE and EMBASE will be searched through Ovid using the MeSH terms given in Appendix A. 139 
Titles will be screened then abstracts of potentially relevant articles will then be retrieved, screened 140 
and full text articles retrieved when necessary to determine inclusion in the study.  Reference lists of 141 
included studies will also be screened, and a search using the ‘Related Articles’ function in PubMed 142 
will capture any further relevant papers. Two individuals will independently screen studies for 143 
inclusion.  Disagreements will be resolved through discussion and consensus.  A flow chart will be 144 
presented to describe the search process and results. 145 
Data extraction 146 
A standardised data collection proforma will be used.  Extracted data will include the participant 147 
details (number and demographics: age, gender and study country), study type (for example 148 
randomised or non-randomised controlled trial, cohort study, case series, qualitative), interventions 149 
(if any), stated outcomes presented in the methods (both primary and secondary), and reported 150 
outcomes.  Outcomes will be extracted verbatim.  As this study focuses on which outcomes are 151 
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reported rather than the value of those outcomes, neither study quality nor risk of bias is relevant so 152 
will not be assessed. Data will be extracted from 10% of studies by two independent reviewers. 153 
Concordance between reviewers will be maximised by discussing in detail the first 10% and coming 154 
to a consensus decision.  Following this, the next 10% will also be extracted independently and 155 
concordance will then be assessed by calculating Kendall’s τ (tau) statistic for the number of 156 
extracted outcomes.  Provided that the concordance between reviewers is high (i.e. a 95% 157 
confidence interval for the value of τ includes zero), the remainder of studies will be extracted by a 158 
single reviewer. If concordance is poor, discrepancies will be investigated and a further 10% of 159 
studies will be double-extracted. If concordance is high at this point, the remainder of studies will be 160 
single extracted, otherwise double extraction and consensus will continue.  161 
Results synthesis 162 
The principal outcome of the systematic review is a list of outcomes, with frequencies of reporting.  163 
Following generation of this (long) list, outcomes will be grouped by the study authors into 164 
appropriate domains in order to draw out common themes for consideration in qualitative focus 165 
groups, discussed below.  For example ’30-day mortality’, ‘in-hospital mortality’ and ’12-month 166 
mortality’ would all be groups into the domain ‘mortality’. 167 
Phase II: Qualitative focus groups 168 
Following the systematic review, we will conduct focus groups with key stakeholders to identify 169 
further outcomes not identified in the systematic review.   The stakeholders will include patients 170 
who have had a major lower limb amputation, family / carers, surgeons, anaesthetists, rehabilitation 171 
physicians, nurses, physiotherapists, occupational therapists, prosthetics technicians, social workers 172 
and other allied groups affiliated to amputees and their care. If a certain group cannot be 173 
represented in a focus group we may interview them on a separate occasion. We anticipate three 174 
focus groups, comprising one with patients and carers, one with doctors, and one with other 175 
healthcare professionals, each with 6-10 participants. This is based on guidance on focus groups in 176 
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terms of numbers of groups and numbers of participants [13]. While the sample population is 177 
relatively small, efforts will be made to include representatives from a range of professions, and 178 
patients (in terms of type of amputation, gender). The research team will be pragmatic in their 179 
sample size and the need to conduct further focus groups will be based on preliminary 180 
analysis/facilitator fieldnotes indicating whether the data collected sufficiently answers the research 181 
question [14]. In line with recent methodological debates on the notion of saturation in qualitative 182 
research [14], we will maintain transparency in our approach by keeping detailed notes on our 183 
sampling strategy. In real terms, decision on whether to sample more participants will be based on 184 
discussions within the research team (GA and LBH) about whether there is sufficient breadth and 185 
depth of data, whether the specific participants represent the research topic, and practical aspects 186 
of recruitment (taking into consideration attempts to invite participants, numbers declined, and 187 
withdrawn). Informed consent will be obtained for all participants by trained study personnel.     188 
Data collection 189 
We will use a flexible, semi-structured topic guide and begin with an open discussion of issues relating 190 
to the care of patients undergoing major lower limb amputation, the level of importance participants 191 
place on these issues, and how these issues may change over time (i.e. over the short and medium 192 
term time periods).  The first part of the interview will be guided by participants themselves, and 193 
reference to the areas identified in the SR will not be revealed. However, after this open discussion, 194 
prompts from the outcome domains developed in the systematic review may be used if areas have 195 
not naturally occurred. The facilitator will use these prompts to explore whether the outcome domains 196 
revealed by the systematic review are relevant to the real-life experiences and attitudes of the focus 197 
group participants and whether they are comprehensive to the concerns and needs of patients with 198 
lower limb amputations. We will encourage participants to initiate and elaborate on topics most 199 
important to them.  Participants will be encouraged to respond directly to other participants’ 200 
responses in order to generate a group discussion. Focus groups are likely to take around 60-90 201 
minutes and will be audio-recorded and transcribed verbatim, with references to identifiable personal 202 
  10 
details removed.  Brief demographic details of participants will be taken by the facilitator.  Field notes 203 
will be made by the facilitator following the focus groups which will include reflections on the process, 204 
overall observations, and relevant contextual details.  The data will be managed using qualitative 205 
coding software (NVivo qualitative analysis software; QSR International Pty Ltd. Version 11).  Data will 206 
be coded, stored and analysed at the Centre for Trials Research, and kept on entrypted storage 207 
devices. The study is coordinated by the CTR, who will monitor and audit study procedures. Monitoring 208 
will be conducted independently by a qualified member of CTR staff not participating in the day-to-209 
day study activities. 210 
Analysis 211 
We will carry out thematic analysis of the focus group transcripts, and the facilitator’s field notes 212 
[15].  Following familiarisation with the data, LBH will develop a way of categorising the data into 213 
themes and subthemes (the analytical framework). We will take an inductive approach, where the 214 
themes are identified directly from the focus group data, without referring to the categories 215 
identified in the SR. LBH and GA will discuss the framework and agree a framework between them. 216 
LBH will then then systematically code the focus group data, using qualitative data analysis software 217 
NVIVO , according to these themes (data topics that are common in the dataset), but also looking for 218 
contradictory views (negative cases). GA will code a proportion of the dataset independently (10-219 
20%) and LBH and GA will meet to discuss discrepancies in coding until consensus is reached. Any 220 
refinements will be made to the analytical framework and reapplied to the data. LBH will then 221 
interpret the coded data, taking into consideration the stakeholder group (i.e. themes according to 222 
patient, carer, health professional type). The next, and final stage of analysis will then involve 223 
considering this interpretation of the focus group data against the outcome domains identified in 224 
the systematic review. GA and LBH will identify: (i) areas where themes in the focus group data are 225 
similar or correspond to those identified in the SR; (ii) areas where new themes were initiated by 226 
focus group participants but were not found in the SR; and (iii) areas where themes were found in 227 
  11 
the SR but not present in the focus group data. By bringing these elements together we will produce 228 
a list of outcome domains to be taken forward to the consensus study. 229 
As we will use an inductive approach in which the data takes centre stage, the theoretical framework 230 
is not predetermined but description will be derived from the data itself. We will take a 231 
phenomenological approach to attempt to uncover the meaning of the ‘lived experience’ of groups 232 
of individuals - in this case people who have undergone major lower limb amputation and their 233 
family, and a range of health professionals involved in the management of patients who have 234 
undergone amputation - on the phenomenon (issues or outcomes of importance to patients after 235 
undergoing major lower limb amputation). As Tavallaei and Talib (2010:575) [16] describe “the 236 
major aim of phenomenology is to ‘reduce’ the experience individuals have about a certain 237 
phenomenon so that finally the description of the universal essence is created which means “to 238 
grasp the very nature of the thing” (VanManen, 1990:177)” [17]. 239 
Phase III: Consensus survey 240 
Following synthesis of results from the systematic review and qualitative focus groups, stakeholders 241 
(patients and health and social care workers) will be surveyed to determine which outcomes should 242 
comprise the core outcome set for studies of lower limb amputation for PAD.  The list of stakeholders 243 
will include those participating in the focus groups in addition to health and social care workers, who 244 
will be invited to contribute via national and international societies, and the corresponding authors of 245 
studies included in Phase I.  This will be a Delphi consensus process [18], and will mainly use an online 246 
survey tool, but a paper version will also be available for participants who prefer this.  Stakeholders 247 
will be asked to rate the putative outcomes on a 1-9 Likert-like scale, with 7-9 labelled as “essential” 248 
(must be reported in all trials), 4-6 as “desirable”, and 1-3 as “not important”.  Outcomes not achieving 249 
a mean score of greater than 6 by the respondents will be eliminated, and the process will proceed to 250 
a second round of voting. 251 
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In the second round, stakeholders will again be asked to rate the putative outcomes as essential (7-252 
9), desirable (4-6) or not important (1-3).  They will also be given the opportunity to propose outcomes 253 
that they feel to be essential but have been excluded from the first round.  Any additional outcomes 254 
proposed in this way will be considered by the study authors, and added to the list of potential core 255 
outcomes for voting.  Outcomes not achieving a mean score of at least 7 will be eliminated, and the 256 
process will proceed to a third round of voting. 257 
In the third round, stakeholders will be asked to rate the putative outcome measures as essential (7-258 
9), desirable (4-6) or not important (1-3).  Outcomes not voted ‘essential’ (7-9) by 75% of the 259 
respondents will be eliminated. 260 
At each stage, participants will be asked to rate outcomes separately for short-term and medium-term 261 
studies.  This is because it is recognised that some outcomes may be considered more or less 262 
important depending upon the timing of the study.  For example stakeholders may consider the rate 263 
of post-operative pneumonia very important for short term studies but less important for medium 264 
term studies, whereas the rate of prosthetic limb prescription may be considered very important for 265 
medium term studies but less important for short term studies. 266 
Phase IV: Results synthesis and Nominal Group analysis 267 
The ultimate goal of this research is to define core sets of short and medium-term outcomes for 268 
reporting by research studies on patients undergoing major lower limb amputation for PAD.  The 269 
results of the consensus survey will therefore be discussed at a face-to-face meeting of key 270 
stakeholders and a nominal group technique applied to determine a list of short term outcomes and 271 
a second list of medium-term outcomes which will represent the core outcome sets.  Stakeholders 272 
will include members of the PLACEMENT Trial Management Group, along with individuals from 273 
professions or specialties not represented by the Group, who participated in the focus groups in 274 
phase II.  A Nominal Group technique will be used rather than a straightforward vote to either 275 
accept or reject the results of the consensus survey because of the risk that by choosing somewhat 276 
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arbitrary levels at which to eliminate outcomes during the Delphi process, it is possible to arrive at 277 
either a COS with an enormous number of items, or a COS with only a very small number of items.  278 
By using a nominal group technique, the members of the face-to-face meeting therefore have the 279 
opportunity to present potential solutions to these problems if they arise, rather that simply voting 280 
to reject the result of the Delphi. 281 
Publication and dissemination of results 282 
All publications and presentations relating to the study will be authorised by the PLACEMENT Trial 283 
Management Group and will be in accordance with the main trial’s publication policy. In addition to 284 
the required final report and monograph for the funding body, we will publish the main study results 285 
in international peer-reviewed open access journals and present at national and international 286 
scientific meetings. With the assistance of our collaborators and lay representatives we will 287 
disseminate the trial findings to a wide audience and vigorously promote uptake of the trial results 288 
into clinical care. This will include presentations at meetings and written executive summaries for 289 
key stakeholder groups such as Secondary Care Trusts, Royal Colleges, Medical Schools, and relevant 290 
patient groups.  Access to the full protocol, anonymised participant-level data, and statistical code 291 
will be available from the study team upon request after the main study results have been 292 
published. 293 
Discussion 294 
Short and medium term outcomes after major lower limb amputation are surprisingly poor, 295 
especially in the UK [2].  Given that the global diabetes epidemic has caused rates of PAD to rise by 296 
over a third in the first decade of the 21st century [1], it is likely that major lower limb amputation 297 
rates will also rise. There is therefore an urgent need for high quality research to improve these 298 
outcomes. Core outcome sets for both short and medium-term outcomes are critical so that trials 299 
can concentrate on the most important issues to patients and healthcare workers in a way that 300 
facilitates future meta-analysis and guideline development.  301 
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Study Status 302 
The systematic review is currently underway. 303 
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